Meibomian gland dysfunction is responsible for the majority of dry eye disease cases in clinical practice, yet a substantial proportion of patients achieve only partial and transient relief from conventional first-line therapies.Warm compresses, lid hygiene, omega-3 supplementation and topical anti-inflammatory agents remain foundational, but they do not fully address the underlying cellular and glandular pathology driving the disease.Low-level light therapy (LLLT), a form of photobiomodulation, has emerged as a mechanism-directed, non-pharmacologic modality with a growing evidence base
